Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

EU Funded Research Project

The new prediction tools developed in this engagement will enable doctors to develop personalized treatments for their patients to ensure the best patient outcomes, while potentially avoiding unnecessary chemotherapy treatment and associated side effects

Dr Máirín Rafferty
CEO
OncoMark Ltd

Project Title

Personalised treatments for cancer patients

Engagement type

EU Funded Research Project

Industry partner

OncoMark is an Irish SME focused on the development and application of biomarker panels, particularly those supporting oncology clinical decisions and drug development.

Challenge

The number of Irish people suffering from colorectal cancer is predicted to increase by 34% in women and 45% in men by 2020. In addition to surgical resection, common adjuvant or neo-adjuvant treatments include radiotherapy and chemotherapy. Yet, cancer cells often are, or become resistant to these treatments. Led by RCSI, the APO-DECIDE research consortium (www.apodecide. eu) is tackling the problem of chemotherapy resistance in colorectal cancer by analyzing protein levels and DNA mutations in individual tumours, and by incorporating this biological data into mathematical models that recapitulate how these entities interact.

RCSI value-add

Expertise in the development of computational approaches to understand and overcome apoptosis sensitivity and resistance and cellular bioenergetics at a systems level along with dedicated support for the co-ordination of EU projects.